A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition

Abstract

Background:Vascular endothelial growth factor (VEGF)-targeting drugs normalise the tumour vasculature and improve access for chemotherapy. However, excessive VEGF inhibition fails to improve clinical outcome, and successive treatment cycles lead to incremental extracellular matrix (ECM) deposition, which limits perfusion and drug delivery. We show here… (More)
DOI: 10.1038/bjc.2017.13

Topics

5 Figures and Tables

Cite this paper

@article{Schiffmann2017ACO, title={A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition}, author={Lars M Schiffmann and M A Brunold and Maxim Liwschitz and Valentin Goede and Sonja Loges and Mark Wroblewski and Alexander Quaas and Hakan Alakus and Dirk Ludger Stippel and Christiane J Bruns and Michael J Hallek and Hamid Kashkar and U. T. Hacker and Oliver Coutelle}, journal={British Journal of Cancer}, year={2017}, volume={116}, pages={600-608} }